The present invention relates to a phenyl-derivative compound substituted with at least two electron acceptors and at least two electron donors. Formula (I) R.sup.AaR.sup.DbR.sup.ScC.sub.6 wherein a is 2, 3 or 4; b is 2, 3 or 4; c is 0, 1 or 2; a+b−c=6; R.sup.A is at each occurrence independently a group with −M-effect; R.sup.B is at each occurrence independently a group with +−M-effect; R.sup.S is as defined in claim 1. Said compound is suited for use in organic electronic devices, particularly in organic electroluminescent devices.

The present invention relates to a phenyl-derivative compound substituted with at least two electron acceptors and at least two electron donors. Formula (I) R.sup.AaR.sup.DbR.sup.ScC.sub.6 wherein a is 2, 3 or 4; b is 2, 3 or 4; c is 0, 1 or 2; a+b−c=6; R.sup.A is at each occurrence independently a group with −M-effect; R.sup.B is at each occurrence independently a group with +−M-effect; R.sup.S is as defined in claim 1. Said compound is suited for use in organic electronic devices, particularly in organic electroluminescent devices.

A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine compound has a good inhibitory effect on ferroptosis and has good drug safety. Moreover, the compound can be used to prepare a ferroptosis inhibitor, and can also be used to prepare a drug for treating diseases related to ferroptosis, such as neurodegenerative diseases, tumors, tissue ischemia reperfusion injury, stroke, cardiovascular diseases, renal failure, and diabetic complications.

The invention relates to a composition for the immediate termination of a free-radical polymerization, the use thereof for the stabilization of free-radically polymerizable monomers against free-radical polymerization and a method for the immediate termination of free-radical polymerizations.

The invention relates to a composition for the immediate termination of a free-radical polymerization, the use thereof for the stabilization of free-radically polymerizable monomers against free-radical polymerization and a method for the immediate termination of free-radical polymerizations.

Tricyclic compounds, and in particular novel dibenzoxazepin derivates are disclosed herein, which were quite surprisingly found as having OMA1 and/or OPA1 modulatory properties. Compounds of present invention may provide useful for the treatment of certain conditions and diseases, which are amenable to OMA1 and/or OPA1-modulatory therapies. Such conditions may include conditions and diseases prevalent in the elderly, including cancer. Pharmaceutical compositions comprising compounds of present invention may be combined with other treatments or further comprise other pharmaceutically active ingredients.

Tricyclic compounds, and in particular novel dibenzoxazepin derivates are disclosed herein, which were quite surprisingly found as having OMA1 and/or OPA1 modulatory properties. Compounds of present invention may provide useful for the treatment of certain conditions and diseases, which are amenable to OMA1 and/or OPA1-modulatory therapies. Such conditions may include conditions and diseases prevalent in the elderly, including cancer. Pharmaceutical compositions comprising compounds of present invention may be combined with other treatments or further comprise other pharmaceutically active ingredients.

The present invention provides a novel ligand compound, a transition metal compound and a catalyst composition including the same.

The present invention relates to: a process for preparing 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide or chloride; a method of converting 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide to 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride; and the purification of 7-bis-(dimethylamino)-phenothiazin-5-ium chloride by crystallization from aqueous solution of hydrochloric acid, leading to a pharmaceutically acceptable 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride (methylthioninium chloride, methylene blue, MTC) of formula I below reported. ##STR00001##

The present invention relates to: a process for preparing 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide or chloride; a method of converting 3,7-bis-(dimethylamino)-phenothiazin-5-ium bromide to 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride; and the purification of 7-bis-(dimethylamino)-phenothiazin-5-ium chloride by crystallization from aqueous solution of hydrochloric acid, leading to a pharmaceutically acceptable 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride (methylthioninium chloride, methylene blue, MTC) of formula I below reported. ##STR00001##